The European Commission has commissioned a study on trends in the falsification of medicinal products and associated measures. The objective of the study is to assess the implementation of the Falsified Medicines Directive (FMD 2011/62/EU), the medicines authentication measures laid down in DR (EU) 2016/161 and their effects (measures on safety features), and to evaluate the adequacy and functioning of the system in place against the objectives and targets of the regulations. The study was contracted to a consortium led by EY Consulting and Ramboll Management Consulting who state, ‘Stakeholder input is crucial in assessing the importance and effectiveness of measures under the Directive, identifying any implementation difficulties or national specificities, evaluating the overall functioning of the system, and providing recommendations for addressing gaps and shaping its future direction’.
You can access/share the survey here.
The survey will be open until 3 July. If you have any technical difficulties in accessing the survey, please contact the study team at: FMDtudy_Ramboll_EY@ramboll.com.
